Prophylix
prophylix.com
Actively hiring
Rare Disease Therapeutics
Drug Discovery
Pediatric Care
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
Sarsia
Momentum
0/100
no fresh signals
Backed byfrom the funds' portfolios and accelerator catalogs
Sarsia Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
US FDA Grants Orphan Drug and Rare Pediatric Disease Designations to GEn1E Lifesciences' Dual Signal Modulator for the Treatment of…
Oak Hill Bio is a clinical-stage biotechnology company focused on acquiring and developing outstanding rare disease drugs that have been…
Abinitio bio is the AI-native operating platform for drug development and manufacturing.
Human cells cannot degrade cholesterol, leading to several chronic and orphan diseases. Repair Biotechnologies’ Cholesterol Degrading…
Babylon is a drug development company pursuing a transformational treatment for Alzheimer’s. Meet our team and explore how we discover…
Precision biomarkers that quantify functional brain change. Supporting drug development and brain health programs.
Overview
Prophylix AS has entered into a definitive agreement with Rallybio, a U.S.-based drug development company, under which Rallybio acquires Prophylix's orphan drug programs, NAITgam and a follow-on therapy.